Americas

Argentina

Spanish

Brazil

Portuguese

Canada

Chile

Spanish

Colombia

Spanish

Mexico

Spanish

Peru

Spanish

United States

English

Asia Pacific

Europe

Austria

German

Belgium

Czech Republic

Czech

Denmark

Norwegian

Finland

Finnish

France

French

Germany

German

Greece

Greek

Hungary

Hungarian

Ireland

English

Italy

Italian

Luxembourg

English

Netherlands

Norway

Norwegian

Poland

Poland

Portugal

Portuguese

Romania

Romanian

Spain

Spanish

Sweden

Swedish

Switzerland

United Kingdom

English

Middle East

Israel

Hebrew

Saudi Arabia

Turkey

Turkish

United Arab Emirates

Other

Other Markets

Distributor Markets
Our Medicines
Search
Search

Working with the NHS

At Bristol Myers Squibb, we recognise the significant challenges facing the NHS. The public rightly want fast access to high quality care at a time and place that is convenient to them.

At the same time, the global recession means budgets are increasingly constrained. The challenge for the NHS, therefore, is to meet these public expectations with tighter resources.

We believe our portfolio of existing and pipeline medicines can be part of the solution to these challenges. These new medicines will offer opportunities for the NHS to provide patients with better outcomes and better quality of life. Yet we also recognise that new treatments will present challenges to the NHS.

New medicines often increase the upfront cost of healthcare. They may also require staff training, new capacity or changes to patient pathways. At a time when resources are stretched it is ever more important that the NHS gets the most out of the new medicines it invests in, in terms of both clinical outcomes and patient experience.

In recognition of this, our approach at Bristol Myers Squibb is to work in partnership with the NHS to make sure it gets maximum value from our medicines.

Our teams are becoming more flexible when it comes to meeting customer needs rather than trying to apply a one-size-fits-all solution. In fact, we are now regularly having conversations with payers about providing a whole service and not just medicines.

Partnerships that bring value to the NHS

In order to meet its chosen strategy, every partnership entered into by Bristol Myers Squibb with the NHS must be underpinned by four key undertakings:

  • Bristol Myers Squibb endeavours to continually develop medicines to meet true unmet medical need across a range of disease areas
  • We are committed to enhancing clinical excellence through clinical research activities
  • We will provide robust evidence on our medicines to support NHS decision makers
  • Bristol Myers Squibb is striving to improve its service delivery so that its medicines reach the right patients at the right time.
NHS Trust Name Collaborative Working Project Documents
UK Oncology Nursing Service (UKONS) Development of a National E-Learning Training programme for NHS Staff undertaking UK Oncology Nursing Service (UKONS) guided 24 Hour Telephone Triage of Oncology/Haematology Patients Outcomes Report
Birmingham and Solihull Clinical Commissioning Group (BSOL CCG) Reducing the number of avoidable Atrial Fibrillation (AF) related strokes across Birmingham and Solihull Clinical Commissioning Group Outcomes Report
Weston Park Cancer Centre (WPCC) part of the Sheffield Teaching Hospitals NHS Foundation Trust Patient Experience Feedback Response to the Rapid Implementation of Virtual Clinics due to COVID-19 Outcomes Report
Macmillan Cancer Support Demonstrating the Value of Prehabilitation through Service and Workforce Efficiencies Summary of the Collaborative Working Agreement
Clatterbridge Cancer Centre NHS Foundation Trust National Immuno-Oncology (IO) Clinical Network – bringing together IO Clinical Leaders as a National Clinical Network to champion and direct IO Service Development Outcomes Report
Newcastle Upon Tyne Hospitals NHS Foundation Trust Optimising future time to diagnosis for the Multiple Myeloma (MM) patient through understanding the current secondary care patient journey to inform a future exemplar pathway Termination of Collaborative Working Agreement
Macmillan Cancer Support Forecasting for innovation: A workforce planning tool Summary of Collaborative Working Agreement
Shine Clinical and Leeds Teaching Hospitals NHS Trust Enhancing Hypertrophic Cardiomyopathy (HCM) care in the Leeds community Termination of Collaborative Working Agreement
Guy’s and St Thomas’ Hospitals NHS Foundation Trust (GSTT part of King’s Health Partners (KHP) Improving care for patients with Hypertrophic Cardiomyopathy (HCM) by embedding digital solutions and service development Summary of Collaborative Working Agreement
Guys’ and St Thomas’ NHS Trust and University Hospitals Birmingham NHS Foundation Trust Implementing guideline-based pathway redesign for Hypertrophic Cardiomyopathy patients Summary of Collaborative Working Agreement
Liverpool Heart and Chest Hospital NHS Foundation Trust Implementation of a pilot community based Inherited Cardiac Conditions (ICC) service Summary of Collaborative Working Agreement
Manchester University NHS Foundation Trust Standardised registry of hypertrophic cardiomyopathy (HCM) patients in the UK as a pilot across several sites in Northern England and Scotland Summary of Collaborative Working Agreement




NO-GB-2500087
Date of preparation: July 2025

AltStyle によって変換されたページ (->オリジナル) /